Echo Therapeutics, Inc. operates as a transdermal medical device company in the United States. The company is involved in developing Prelude SkinPrep System, which is a platform technology to allow painless skin permeation that would enable both needle-free drug delivery and analyte extraction; and Symphony tCGM System, a non-invasive, wireless, and transdermal continuous glucose monitoring system for use in hospital critical care units and for patients with diabetes. It also engages in the development of specialty pharmaceuticals based on its proprietary AzoneTS transdermal drug reformulation technology. The company’s drug candidate is Durhalieve, an AzoneTS formulation of triamcinolone acetonide for the treatment of corticosteroid-responsive dermatoses. It has a licensing agreement with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude for skin preparation prior to the application of topical anesthetics prior to a range of needle-based medical procedures in North America and the United Kingdom; and a license agreement with Handok Pharmaceuticals Co., Ltd. to develop, market, sell, and distribute Symphony to medical facilities and diabetics in South Korea. Echo Therapeutics, Inc. was founded in 1989 and is headquartered in Philadelphia, Pennsylvania.

Key Statistics